Metsera (NASDAQ:MTSR) Sets New 1-Year High – Should You Buy?

Metsera, Inc. (NASDAQ:MTSRGet Free Report)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $31.64 and last traded at $30.19, with a volume of 5601 shares traded. The stock had previously closed at $29.50.

Metsera Stock Performance

Metsera Company Profile

(Get Free Report)

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

Featured Stories

Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.